J&J Covid-19 vaccine lasts at least 8 months, protects against Delta variant, studies find


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
J&J Vaccine gets emergency FDA approval

The Johnson & Johnson coronavirus vaccine provides immunity that lasts at least eight months, and it appears to provide adequate protection against the worrying Delta variant, the company said in a statement Thursday night.

"Current data for the eight months studied so far show that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time," Dr. Mathai Mammen, head of research and development at J&J's Janssen vaccine arm, said in a statement.
The company said one dose of the vaccine elicits both a lasting antibody response and generates immune cells called T-cells that last eight months, also.

Dr. Dan Barouch of Beth Israel Deaconess Medical Center and Harvard Medical School and colleagues tested blood taken from 20 volunteers in an early stage, Phase 1/2 trial of the vaccine.
"These data are promising and reassuring," Barouch told CNN. Barouch has submitted his findings to the BioRxiv preprint server.
"Data showed that T-cell responses -- including CD8+ T-cells that seek out and destroy infected cells -- persisted over the eight-month timeframe examined," the company said.
These are not real-world efficacy data, but antibody and T-cell responses usually indicate protection, Barouch said.

Pfizer/BioNTech and Moderna have both said their two-dose vaccines are protective for at least six months and researchers at Washington University in St. Louis reported earlier this week that their studies of vaccinated volunteers indicate protection from the vaccines should last much longer than that-- even for years. They did not test the J&J vaccine.

Barouch's team also tested blood from the vaccinated volunteers against the most worrying variants of the virus, including the Delta or B.1.617.2 variant first seen in India, the B.1.351 or Beta variant first seen in South Africa, and the P.1 or Gamma variant spreading in Brazil.

"We see robust neutralizing antibody coverage of the variant," Barouch said. Neutralizing antibodies are the immune system proteins that inactivate a virus before it can replicate.

"A single dose of the Johnson & Johnson COVID-19 vaccine generated neutralizing antibodies against a range of SARS-CoV-2 variants of concern, which increased over time, including against the increasingly prevalent and more transmissible Delta (B.1.617.2) variant, the partially neutralization-resistant Beta (B.1.351), the Gamma (P.1) variants and others, including the Alpha (B.1.1.7), Epsilon (B.1.429), Kappa (B.1.617.1) and D614G variants, as well as the original SARS-CoV-2 strain," the company said.

Separately, a Janssen team in the Netherlands studied blood taken from eight vaccinated volunteers in the company's Phase 3 trial and found similar results against the variants.

Earlier Thursday, J&J said a second or booster dose of its vaccine would not be necessary.

Dr. Anthony Fauci agreed. "With regard to the idea of boosting, there's a lot of talk about that -- but right now I think we still need to remember that in fact, the J&J vaccine is a highly effective vaccine that has been recommended very clearly and has received an emergency use authorization," Fauci, who is director of the National Institute of Allergy and Infectious Diseases, told a White House briefing Thursday.

However, J&J, along with the US National Institutes of Health, is testing to see whether giving people two doses of its vaccine will provide better protection.

Story Courtesy

https://edition.cnn.com/2021/07/01/health/johnson-vaccine-delta-variant/index.html

Tags : #JohnsonJohnson #DeltaVariant #Covid19Vaccine #smitakumar #medicircle

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Smart Operating Rooms: The Future of Hospital OTNovember 21, 2026
Smartphone Diagnostics: Phones as Medical Screening ToolsNovember 21, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026